Modified RNAi Agents for TTR Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for TTR-associated diseases, which are characterized by the deposition of amyloid fibrils composed of misfolded transthyretin (TTR) protein, leading to various forms of amyloidosis affecting the nervous system, heart, and other organs.
Innovation Solution
The use of RNAi agents, specifically double-stranded RNAi agents with modified nucleotides and specific modifications such as 2′-fluoro and phosphorothioate linkages, targeted to the TTR gene, which effectively silence TTR gene expression by binding to specific regions of the TTR mRNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional RNAi agents are used to silence TTR gene expression, then TTR protein production is reduced, but the agents suffer from poor stability and low efficacy in vivo
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of RNAi agents through multiple nucleotide modifications (2'-O-methyl, 2'-fluoro, LNA), phosphorothioate backbone modifications, and conjugation to cholesterol or GalNAc ligands. These chemical parameter changes enhance both the stability and efficacy of the RNAi agents in vivo while maintaining their gene silencing function.
2Reliability
If highly modified RNAi agents are used to improve stability and efficacy, then TTR gene silencing activity is enhanced, but the complexity of the agent structure increases
Solution Approach 1:
The patent employs composite materials by combining multiple modification types within single RNAi agents: modified nucleotides (2'-O-methyl, 2'-fluoro, LNA) are integrated with phosphorothioate backbone modifications and conjugated to ligands (cholesterol or GalNAc). This composite approach creates highly effective and stable agents that overcome the limitations of single-modification strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These RNAi agents demonstrate enhanced TTR gene silencing activity, leading to reduced expression and production of the TTR protein, thereby potentially treating or preventing TTR-associated diseases by inhibiting amyloid formation.
Implementation Method 1
The use of RNAi agents, specifically double-stranded RNAi agents with modified nucleotides and specific modifications such as 2′-fluoro and phosphorothioate linkages, targeted to the TTR gene, which effectively silence TTR gene expression by binding to specific regions of the TTR mRNA.
Data Source
AI summary
The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.